A PHASE 3, MULTICENTER, RANDOMIZED, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
A PHASE 3, MULTICENTER, RANDOMIZED, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Inclusion Criteria:
Exclusion Criteria:
Mesa, Arizona 85206, United States
Phoenix, Arizona 85020, United States
Albuquerque, New Mexico 87106, United States
Charlotte, North Carolina 28207-1198, United States
Rock Hill, South Carolina 29732, United States
Salt Lake City, Utah 84121, United States